The global spinal cord trauma treatment market is expected to grow at a CAGR of around 3.6% from 2020 to 2027 and expected to reach the market value of around US$ 4,547.2 Mn by 2027.
Damage to the spinal cord can occur in several ways; most common cause being external trauma. A spinal cord injury is damage to any part of the spinal cord or nerves at the end of the spinal canal (cauda equina) that often causes permanent changes in strength, sensation, and other body functions below the site of injury. Spinal cord injury tends to affect more men as compared to women and majority of the people who sustains a spinal cord injury is between the ages of 16 and 30 due to increased likelihood of risky behavior. Currently, there are no ways to reverse damage to the spinal cord. However, researchers are continuously working on new treatments, involving prostheses and medications that may promote regeneration of nerve cells or improve function of the nerves that remain after a spinal cord injury (SCI). According to the World Health Organization (WHO), there is no real estimate of global prevalence, but estimated annual global incidences is 40 to 80 cases per million population. Up to 90% of these cases care caused due to traumatic cases though the population of non-traumatic spinal cord injury appears to be growing.
Presence of the stellar industry enhances the growth of spinal cord trauma treatment market
Continual research and presence of stellar industry for global healthcare enhances the growth of the market. The stellar study is a phase 3 clinical study that is designed to evaluate the efficacy and safety of Eflornithine in combination with Lomustine compared to Lomustine taken alone in patients suffering from Anaplastic Astrocytoma i.e. recurrence or progression after radiation therapy and Temozolomide (Temodar®) chemotherapy. Anaplastic Astrocytoma originates from astrocytes, a type of cell that normally wraps and protects nerves in the brain and spinal cord. Unfortunately, the exact cause of Anaplastic Astrocytoma is not known. On the other hand, Eflornithine acts as a molecule that targets a key enzyme called ornithine decarboxylase. According to the studies conducted by the American Brain Tumor Association on humans and animals, Eflornithine has shown good response towards delaying or stoppage of the growth of brain cancer as well as other kinds of cancer cells.
Cell Pores discovery: A new hope for the patients with spinal cord injury
Scientists have discovered a new treatment that dramatically reduces swelling after brain and spinal cord injuries. The new treatment is developed by a team of international scientists working at Aston University and the University of Birmingham, (UK), Harvard Medical School (US), University of Calgary (Canada), Lund University (Sweden) and Copenhagen University (Denmark). The researchers used existing licenses of anti-psychotic medicine trifluoperazine (TFP). Testing the treatment on injured rats, it was found that those animals that are given a single dose of the drug at the trauma site recovered full movement and sensitivity in less than two weeks. The treatment works by counteracting the cells normal reaction to a loss of oxygen caused by trauma in the CNS, the brain and the spinal cord. TFP is already licensed for use in humans by the US Federal Drug Administration (FDA) and the UK National Institute for Health and Care Excellence (NICE)
Rising incidences of sports injuries bolster the growth of the global spinal cord trauma treatment market
According to the Australian Institute of Health and Welfare, the 3 most often associated sports related spinal injury are water sports, wheeled motor sports, and equestrian activities. The average acute-care cost of the first admission record for a cervical SCI was US$ 67,523 that was the highest for any type of sports related injury. A thoracic lumbosacral SCI was the second most expensive type of sports related injury at an average cost of US$ 37,797 per person. Just on one-quarter (26%) of the traumatic SCI cases were reported to the ASCIR for 2015-2016, occurred while the person engaged in sports or leisure activities is high prevalent in males than women that is 89% (58 of 65 cases). Moreover, 20% of the SCI were reported due to water related event whereas pedal cyclist contribute greatest proportion to sport and leisure SCI cases (14 cases or 22%) while motorcyclist contributes 15%.
Spinal cord trauma treatment market is treatment type, injury type, and end-user.
By treatment type, the market is segmented as corticosteroid, spinal traction, and surgery. By injury, the market is bifurcated into partial spinal cord injury and complete spinal cord injury. By end-user, the market is classified into trauma centers and hospitals.
Based on treatment type, corticosteroids is fastest growing lucrative segment
After the initial tissue damage associated with spinal cord injury, the inflammatory response is controllable. The inflammatory response is conducted by tissue ischemia, oxidative stress, and immune response. Steroids such as methylprednisolone are utilized in the reduction of oxidative stress and acts as a primary degenerative event post trauma. Every year, about 40 million people suffer globally from spinal cord injury as per the estimates release by the Cochrane. Several drugs are prescribed to patients that reduce the extent of permanent paralysis. In all the research conducted in all seven trials involves just one steroid effective that is methylprednisolone. The results show that the treatment with the steroid methylprednisolone does improve movement but it should start soon after the injury has happened within no more than eight hours. It should be continued for 24 to 48 hours. The treatment offers the patient a normal amount of movement and more research is necessary with steroids through combination with other drugs.
North America recorded largest market share followed by Europe in Spinal Cord Trauma Treatment Market
Availability of treatment options in North America for Spinal Cord Trauma Treatment enhances the regional market growth. Corticosteroid and spinal traction have gained significant attention in North America region owing to rising incidences of spinal cord injuries (SCI). Additionally, the North America regional market is projected to expand as people from across the world travel to the US for better treatments. According to the National Institute of Neurological Disorders and Stroke, it is estimated that 12,000 spinal cord injuries are recorded annually in the US alone. Moreover, more than a quarter of a million Americans are currently living with spinal cord injuries the cost of managing the care of spinal cord injury patient is US$ 3 Bn per year. Tech advancements for diagnosis and rehabilitation centers are well established in the US have gained huge prominence globally for people travelling for the treatment of spinal cord traumatic cases.
Key companies profiled in this report involve Asterias Biotherapeutics, BioArctic AB, ReNetX Bio. , BioTime, Inc., Kringle Pharma, Inc., and InVivo Therapeutics., and among others.
Market By Treatment Type
Market By Injury
Partial Spinal Cord Injury
Complete Spinal Cord Injury
Market By End-User
Market By Geography
Middle East & Africa
Spinal cord trauma treatment market is expected to reach a market value of around US$ 4,547.2 Mn by 2027.
The spinal cord trauma treatment market is expected to grow at a CAGR of around 3.6% from 2020 to 2027.
Surgery type is the leading segment by treatment type.
Research and development activity is one of the prominent factors that drive the demand for spinal cord trauma treatment market.
Asterias Biotherapeutics , BioArctic AB , ReNetX Bio. , BioTime, Inc., Kringle Pharma, Inc., and InVivo Therapeutics., and among others.
North America is anticipated to grab the highest market share in the regional market
Europe is expected to be the fastest growing market in the forthcoming years